IGC Pharma(US:IGC) ZACKS·2025-06-27 22:46Group 1 - IGC Pharma, Inc. reported a quarterly loss of $0.01 per share, better than the Zacks Consensus Estimate of a loss of $0.02, representing an earnings surprise of +50.00% [1] - The company posted revenues of $0.33 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 6.45%, compared to revenues of $0.29 million a year ago [2] - IGC Pharma has surpassed consensus EPS estimates three times over the last four quarters [2] Group 2 - The stock has underperformed the market, losing about 7.7% since the beginning of the year, while the S&P 500 gained 4.4% [3] - The current consensus EPS estimate for the coming quarter is -$0.03 on revenues of $0.33 million, and -$0.11 on revenues of $1.5 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Drugs is in the top 33% of over 250 Zacks industries, indicating a favorable outlook for the industry [8]